Headline News

 

AbbVie presents compelling ovarian cancer data that could significantly expand ELAHERE’s market reach

Posted on April 14, 2026

Novo Nordisk secures EU regulatory approval to streamline Wegovy distribution, paving way for broader home delivery

Posted on April 14, 2026

Novo Nordisk partners with OpenAI to accelerate drug discovery

Posted on April 14, 2026

Revolution Medicines opens first line pancreatic cancer trial as Daraxonrasib programme expands

Posted on April 14, 2026

Neurocrine Biosciences set to acquires Soleno Therapeutics in $2.9 billion rare disease deal

Posted on April 14, 2026

Spyre Therapeutics showcases positive phase 2 data for SPY001 in ulcerative colitis, opening enrolment for combination cohorts

Posted on April 14, 2026

Daraxonrasib highlights overall survival benefit in patients with metastatic pancreatic cancer

Posted on April 14, 2026

Gilead moves to bolster cancer pipeline with €3 billion german biotech buyout

Posted on April 14, 2026

AstraZeneca’s Alexion unit set to showcase broad rare disease data at AAN 2026

Posted on April 14, 2026

Lilly’s Foundayo (new oral GLP-1 pill for weight loss) now available in the U.S.

Posted on April 14, 2026

INLEXZO received permanent billing code highlighting access for patients with certain bladder cancers

Posted on April 07, 2026

Amgen announces new positive topline phase 3 results for subcutaneous Tepezza

Posted on April 07, 2026

Allergan Aesthetics announces all access CoolMonth with deals on coolsculpting

Posted on April 07, 2026

Wegovy highlighted greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison

Posted on April 06, 2026

Astrazeneca’s Efzimfotase alfa highlighted positive results from Phase III clinical programme in hypophosphatasia

Posted on April 06, 2026